Vitalhub Corp

Vitalhub Corp maintains a strong liquidity position, with a current ratio of 2.4 and cash and equivalents of CAD 57.6 million, which is well above the industry median. The company's debt-to-equity ratio is 0.01, indicating a conservative capital structure with minimal leverage. Free cash flow of CAD 16.8 million supports operational flexibility and potential reinvestment. Profitability metrics show a return on equity (ROE) of 2.3% and a return on assets (ROA) of 1.73%, which are below the industry median for healthcare software providers. Operating income of CAD 3.6 million and a net income of CAD 6.1 million suggest moderate profitability, with gross profit margin at 80.4%. These figures indicate a need for improvement in cost management or pricing power to align with industry benchmarks. The company's revenue is concentrated in the United Kingdom and Canada, with no disclosed breakdown of geographic contribution. This concentration may expose Vitalhub to regional economic or regulatory risks. The product portfolio includes multiple software modules, but no segment-specific revenue data is available, limiting visibility into the performance of individual offerings. Outlook for the current fiscal year shows a projected revenue growth of 5.2%, with a 3.8% increase expected in the following year. This growth is driven by expansion in existing markets and the adoption of new software modules. Historical revenue growth has averaged 4.5% annually, suggesting a stable but not aggressive growth trajectory. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low dilution potential, as shares outstanding remain unchanged between basic and diluted counts. No recent equity issuance or ATM/shelf registration activity has been reported, supporting the low dilution risk rating. Recent events include the release of Q4 financial results and a positive analyst outlook, with a mean price target of CAD 12.62 and a median of CAD 12.50. Analysts have issued 10 "buy" recommendations and 1 "strong buy," with no "hold" or "sell" ratings. No material regulatory or litigation events have been disclosed in the latest filings.